Pancreatic Cancer Research

ResearcherUniversity of California, Los AngelesNo recent work listed

Katsunori Imai

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0549-1825; OpenAlex author ID A5065485846. Sources: OpenAlex.

Their work

Papers
25 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
59
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: 1 paper · 2016: 1 paper · 2017: 1 paper · 2018: 4 papers · 2019: 2 papers · 2020: 3 papers · 2021: 6 papers · 2022: 3 papers · 2023: 3 papers

Papers 25

  1. Hyperglycaemia induces metabolic reprogramming into a glycolytic phenotype and promotes epithelial-mesenchymal transitions via YAP/TAZ-Hedgehog signalling axis… Co-author DOI 10.1038/s41416-022-02106-9↗
  2. The Prognostic Role of Serine Racemase in Patients With Pancreatic Cancer: A New Marker in Cancer Metabolism. Co-author DOI 10.1097/mpa.0000000000002210↗
  3. Cancer-associated fibroblasts reuse cancer-derived lactate to maintain a fibrotic and immunosuppressive microenvironment in pancreatic cancer. Co-author DOI 10.1172/jci.insight.163022↗
  4. Thrombospondin-1 overexpression stimulates loss of Smad4 and accelerates malignant behavior via TGF-β signal activation in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.tranon.2022.101533↗
  5. Survival Impact of Perioperative Red Blood Cell Transfusion During Pancreatectomy in Patients With Pancreatic Ductal Adenocarcinoma: A Propensity Score Matchin… Co-author DOI 10.1097/mpa.0000000000001997↗
  6. High Expression of Bloom Syndrome Helicase is a Key Factor for Poor Prognosis and Advanced Malignancy in Patients with Pancreatic Cancer: A Retrospective Study. Co-author DOI 10.1245/s10434-022-11500-9↗
  7. Frailty is associated with poor prognosis after resection for pancreatic cancer. Co-author DOI 10.1007/s10147-021-01983-z↗
  8. Metabolic shift to serine biosynthesis through 3-PG accumulation and PHGDH induction promotes tumor growth in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2021.09.007↗
  9. Toward an Optimized Staging System for Pancreatic Ductal Adenocarcinoma: A Clinically Interpretable, Artificial Intelligence-Based Model. Co-author DOI 10.1200/cci.21.00001↗
  10. Prognostic Value of the Preoperative Tumor Marker Index in Resected Pancreatic Ductal Adenocarcinoma: A Retrospective Single-Institution Study. Co-author DOI 10.1245/s10434-020-09022-3↗
  11. High ARHGEF2 (GEF-H1) Expression is Associated with Poor Prognosis Via Cell Cycle Regulation in Patients with Pancreatic Cancer. Co-author DOI 10.1245/s10434-020-09383-9↗
  12. Proteomic Analysis of Malignant Ascites From Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.21873/anticanres.15071↗
  13. Postoperative nonalcoholic fatty liver disease is correlated with malnutrition leading to an unpreferable clinical course for pancreatic cancer patients underg… Co-author DOI 10.1007/s00595-019-01866-x↗
  14. Successful Treatment for the Recurrent Liver Metastases of the Pancreatic Cancer by Multimodality Therapy. Co-author DOI 10.1097/mpa.0000000000001622↗
  15. Prognostic Impact of Coagulation Activity in Patients Undergoing Curative Resection for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.21873/invivo.12111↗
  16. PD-L1 expression enhancement by infiltrating macrophage-derived tumor necrosis factor-α leads to poor pancreatic cancer prognosis. First author DOI 10.1111/cas.13874↗
  17. Cellular Senescence, Represented by Expression of Caveolin-1, in Cancer-Associated Fibroblasts Promotes Tumor Invasion in Pancreatic Cancer. Co-author DOI 10.1245/s10434-019-07266-2↗
  18. Clinical usefulness of postoperative C-reactive protein/albumin ratio in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.amjsurg.2017.08.016↗
  19. Serum Marker Score Based on Prognostic Nutrition Index, Carcinoembryonic Antigen, and Carbohydrate Antigen 19-9 Is Associated With Recurrence for Patients Unde… Co-author DOI 10.1097/mpa.0000000000001146↗
  20. Downregulation of 15-hydroxyprostaglandin dehydrogenase by interleukin-1β from activated macrophages leads to poor prognosis in pancreatic cancer. Co-author DOI 10.1111/cas.13467↗
  21. Multiple Primary Cancers in Patients with Pancreatic Cancer. Co-author DOI 10.1177/000313481808401205↗
  22. Pancreatic Cancer Arising From the Remnant Pancreas: Is It a Local Recurrence or New Primary Lesion? Co-author DOI 10.1097/mpa.0000000000000897↗
  23. The diagnostic role of the neutrophil-to-lymphocyte ratio in predicting pancreatic ductal adenocarcinoma in patients with pancreatic diseases. Co-author DOI 10.1007/s10147-016-0975-z↗
  24. Significance of P-cadherin overexpression and possible mechanism of its regulation in intrahepatic cholangiocarcinoma and pancreatic cancer. First author DOI 10.1111/cas.12732↗
  25. Identification of HLA-A2-restricted CTL epitopes of a novel tumour-associated antigen, KIF20A, overexpressed in pancreatic cancer. Co-author DOI 10.1038/sj.bjc.6606052↗

Closest collaborators

The 25 strongest of 59 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hiromitsu Hayashi · 16 shared papers, 2015–2023 · strength 1.87
  2. Hideo Baba · 15 shared papers, 2011–2023 · strength 1.41
  3. Shigeki Nakagawa · 14 shared papers, 2015–2023 · strength 1.39
  4. Rumi Itoyama · 9 shared papers, 2018–2023 · strength 0.97
  5. Tatsunori Miyata · 9 shared papers, 2018–2023 · strength 0.92
  6. Akira Chikamoto · 11 shared papers, 2015–2022 · strength 0.88
  7. Norio Uemura · 7 shared papers, 2020–2023 · strength 0.86
  8. Kosuke Mima · 6 shared papers, 2021–2023 · strength 0.84
  9. Takayoshi Kaida · 7 shared papers, 2016–2023 · strength 0.82
  10. Takanobu Yamao · 8 shared papers, 2018–2021 · strength 0.73
  11. Zhao Liu · 5 shared papers, 2020–2023 · strength 0.70
  12. Fumimasa Kitamura · 6 shared papers, 2020–2023 · strength 0.69
  13. Masayo Tsukamoto · 7 shared papers, 2018–2023 · strength 0.68
  14. Hirohisa Okabe · 8 shared papers, 2015–2021 · strength 0.63
  15. Yosuke Nakao · 6 shared papers, 2019–2021 · strength 0.62
  16. Kazuki Matsumura · 5 shared papers, 2020–2023 · strength 0.62
  17. Yuki Kitano · 7 shared papers, 2016–2022 · strength 0.60
  18. Takatsugu Ishimoto · 6 shared papers, 2018–2023 · strength 0.56
  19. Kota Arima · 7 shared papers, 2016–2021 · strength 0.51
  20. Naoki Umezaki · 5 shared papers, 2018–2021 · strength 0.43
  21. Daisuke Hashimoto · 6 shared papers, 2016–2018 · strength 0.40
  22. Takashi Matsumoto · 3 shared papers, 2021–2022 · strength 0.40
  23. Hideo Baba · 3 shared papers, 2021–2022 · strength 0.39
  24. Kensuke Yamamura · 5 shared papers, 2016–2020 · strength 0.38
  25. Chuan Lan · 2 shared papers, 2022–2023 · strength 0.31

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.